Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 27, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 27, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg".